Nama's AI scorecard currently rates ImmunityBio Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does IBRX report earnings?

ImmunityBio's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.05.

What is the IBRX price target?

The median analyst price target from 4 analysts is $14.50, with a range of $12.00 – $16.00.

Is IBRX Shariah compliant?

Nama's AAOIFI-style screen reads ImmunityBio as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

ImmunityBio (IBRX)

Healthcare · Biotechnology · NASDAQ

ImmunityBio (IBRX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $9.15B and a free-cash-flow yield of -3.9%. Over the most recent reported fiscal year, revenue grew 668.3%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +359.9% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-30.6%

How far the last close sits under the highest price of the past five years.

Market cap	$9.15B
Trailing P/E	—
Price / book	—
Price / sales	54.0
FCF yield	-3.9%
Dividend yield	—
Gross margin	99.3%
Operating margin	-151.9%
Net margin	-598.6%
Revenue growth (YoY)	+668.3%
Revenue growth (3-yr annual)	+678.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

IBRX earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.05). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 4, 2026	-$0.22	-$0.08	-175.0%	$51.24M
Q1 2026	May 7, 2026	-$0.08	-$0.07	-14.3%	$44.21M
Q4 2025	Feb 23, 2026	-$0.06	-$0.10	+40.0%	$38.28M
Q3 2025	Nov 4, 2025	-$0.07	-$0.10	+30.0%	$32.06M

IBRX analyst price target

Median target $14.50 from 4 analysts, ranging $12.00 – $16.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live IBRX data on Nama Insights →

Recent Congressional trades

ImmunityBio trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Buy	$1,001 - $15,000	Oct 12, 2026
Lisa McClain	House	Buy	$1,001 - $15,000	Oct 12, 2026

IBRX FAQ

Is IBRX a buy?: Nama's AI scorecard currently rates ImmunityBio Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does IBRX report earnings?: ImmunityBio's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.05.
What is the IBRX price target?: The median analyst price target from 4 analysts is $14.50, with a range of $12.00 – $16.00.
Is IBRX Shariah compliant?: Nama's AAOIFI-style screen reads ImmunityBio as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.